Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × NSCLC × Neoadjuvant Therapy × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 5 Rectal Neoplasms 2 Esophageal Squamous Cell Carcinoma 2 Waldenstrom Macroglobulinemia 1 Triple Negative Breast Neoplasms 1 Stage III and IV Ovarian Cancer 1 Squamous Cell Carcinoma of Head and Neck 1 Recurrence 1 Pathologic Complete Response 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Osteosarcoma 1 Neoplasm, Residual 1 NSCLC 1 Muscle-Invasive Bladder Carcinoma 1 Lymphoma, Large B-Cell, Diffuse 1 Lung Neoplasms 1 Locally Advanced Cervical Cancer 1 Laryngeal Neoplasms 1 Hypopharyngeal Neoplasms 1 Head and Neck Neoplasms 1 Fallopian Tube Neoplasms 1 Esophageal Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Non-Small-Cell Lung 1 Anxiety Disorders 1

Interventions

Surgical Procedures, Operative 2 Carboplatin 2 toripalimab 1 tislelizumab 1 surufatinib 1 osimertinib 1 anlotinib 1 Radiotherapy 1 Radiosurgery 1 Platinum Compounds 1 Pemetrexed 1 Paclitaxel 1 Neoadjuvant Therapy 1 Drug Therapy 1 Diphenhydramine 1 Cisplatin 1 Chemotherapy, Adjuvant 1 Chemoradiotherapy 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07089199 2025-07-28

TitAN

Qilu Hospital of Shandong University

Phase 2 Not yet recruiting

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡